600276 恒瑞医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入23,188,08214.85%27,984,60522,819,78521,275,27125,905,526
减:营业总成本16,915,65012.10%21,008,00118,214,15317,747,08421,792,969
    其中:营业成本3,195,44112.79%3,848,1773,525,2483,486,6393,741,799
               财务费用(333,066)-25.64%(572,732)(478,390)(470,867)(337,956)
               资产减值损失(13,599)-247.02%(32,538)(107,217)(146,684)(13,861)
公允价值变动收益97,800926.26%108,631(58,257)76,50336,233
投资收益(40,823)29.93%4,279(49,157)387,365213,434
    其中:对联营企业和合营企业的投资收益(55,500)2.35%(21,581)(72,696)(62,996)(6,940)
营业利润6,624,51223.93%7,490,6324,909,9054,111,9604,664,816
利润总额6,412,00826.05%7,169,6904,667,1103,968,4924,466,309
减:所得税费用651,77338.55%832,695389,289153,351(17,718)
净利润5,760,23524.78%6,336,9954,277,8213,815,1424,484,027
减:非控股权益9,066-379.31%468(24,615)(91,233)(46,191)
股东净利润5,751,17024.50%6,336,5274,302,4363,906,3754,530,218

市场价值指针
每股收益 (元) *0.89021.92%1.0000.6800.6100.710
每股派息 (元) *----0.2000.2000.1600.160
每股净资产 (元) *8.96530.67%7.1366.3445.9295.473
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容